Company
AstraZeneca
161 published works
Big Molecule Watch
Teva and Samsung Bioepis Add Up to Six Biosimilar Candidates to Partnership
On October 1, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) and Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced a new global license, development, and commercialization agreement for up to six potential…
The IPKat
The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)
The Federal Circuit's decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to…
RF EMerge
The Evolving Law of Enablement: Federal Circuit Decisions in Wyeth and Teva Form a “Yin and Yang” Framework
By Aydin H. Harston, Anh-Thu Lam
Two Federal Circuit decisions, three months apart, analyzed enablement of similarly broad method-of-treatment claims, but reached opposite outcomes. In April, the court reversed a JMOL of invalidity and reinstated a…
Drug & Device Law
Tenth Circuit Holds that PREP Act Preempts Vaccine Breach of Contract Claim
Dressen v. AstraZeneca Pharmaceuticals LP, 2026 WL 2122898(10th Cir. July 23, 2026), extends to four weeks our streak of discussing favorable vaccine decisions – this time involving product liability. In…
Original Source
Texas AG Secures Nearly $34 Million Settlement with Pharmaceutical Company, Reinforcing Active Ongoing THFPA Enforcement
By Jaime L.M. Jones, Kenneth G. Coffin, Matt Bergs, Anna M. Schmitt
The Texas Attorney General (“Texas AG”) recently announced a settlement with AstraZeneca Pharmaceuticals LP (“AstraZeneca”) for $33,998,000 to resolve allegations under the Texas Health Care Program Fraud Prevention Act (“THFPA”)…
Drug Injury Watch
Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs
By Tom Lamb
2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study (Posted by Tom Lamb at Drug Injury Watch) This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION)…
Napoli Shkolnik Blog
Andexanet Alfa (Andexxa) Withdrawn from U.S. Market: What Patients Need to Know
by Christopher R. LoPalo, Partner AstraZeneca has withdrawn Andexxa (andexanet alfa) from the United States market effective December 22, 2025. Patients who experienced adverse health outcomes, complications, or injuries related…
Healthcare Law Blog
Preparing for HRSA’s 340B Rebate Model Pilot Program and the Beacon Platform
By Amanda Bogle, Todd Rosenberg
On October 30, HRSA announced that it had selected eight drug manufacturers to participate in its 340B Rebate Model Pilot Program, spanning 10 drugs representing a range of widely used…
The Korean Law Blog
South Korean Court Recognizes Causal Link Between COVID-19 Vaccine and Neurological Injury
By Sean Hayes
Korea is leading the way, through its courts, in providing compensation for damages allegedly caused by the COVID-19 Vaccination. A recent ruling by the Seoul Administrative Court has marked a…
UK Immigration Blog
Sponsor Licence List UK: How To Find Companies That Can Sponsor Visas
Key Takeaways The Register of Licensed Sponsors is the sole authoritative record of organisations legally permitted to assign Certificates of Sponsorship. Apply the primary filter sequence – A-rated licence, Skilled…